Connect with us

Cannabis News

More Than 200,000 People Were Arrested For Marijuana In The U.S. Last Year, FBI Data Shows

Published

3 months ago

on

Nearly 188,000 people were arrested in the US last year for possession of marijuana, according to the FBI’s latest annual crime report, and another 16,000 for selling or growing cannabis. However, these figures are underestimated given the inconsistencies in federal data and questions about the agency’s methodology.

The entire 2024 data set is based on more than 14 million crimes reported to the Uniform Crime Reporting (UCR) Program, which is used to document and analyze national crime trends. The report covers 95.6 percent of the U.S. population, the FBI said.

This latest data shows that cannabis-related crimes decreased slightly compared to 2023, from 200,306 possession arrests to 187,792 in 2024 and from 16,844 sales or manufacturing arrests to 16,244.

Advocates see the reduction as a reflection of the success of the legalization movement spreading at the state level, but also point out that marijuana is still the most commonly arrested illegal substance in Americans’ “war on drugs.”

“While the total number of marijuana-related arrests has dropped nationwide in recent years, it’s clear that marijuana-related charges are still a major driver of drug war enforcement in the United States,” NORML Deputy Director Paul Armentano told Marijuana Moment.

In the new report, 27 percent of all drug possession arrests were for marijuana, more than for any other substance specifically listed.

Because not all agencies provide complete data for reporting periods, the FBI explained that the bureau calculates estimated crime numbers by essentially extrapolating “using the data provided following a standard estimation procedure.” In terms of total arrests reported for the category called “drug/narcotics,” for example, the FBI said there were 831,446 arrests.

At the same time, frustrations over the inconsistency of the FBI the data Reports of cannabis and other drug arrest trends have been maintained. Different sections of the report report different numbers for seemingly similar categories of crime.

An FBI chart says there were 1,413,223 “drug/narcotics crimes” in 2024. Another uses the figure of 1,577,175 in the same heading. A third total is 1,870,804.

Another section says there were 822,488 arrests for drug abuse violations in 2024, about 12 percent of the estimated 7.5 million arrests nationwide.

The FBI data also shows trends over time, indicating that 1,055,013 drug-related charges were filed in 2015 and 600,400 drug-related charges were filed in 2024, a decrease of about 43 percent, although it is unclear how much of the change is due to changes in the agency’s arrest practices and methods. State drug laws over the past decade.

In terms of controlled substance seizures in 2024, the agency said 386,540 cases of marijuana were seized out of a total of 1,072,704 drug seizures, about 36 percent of enforcement actions.

Lawmakers, researchers, and the media rely on FBI arrest data to understand and contextualize law enforcement trends. Not only do inconsistencies affect the public’s understanding of crime and law enforcement, but also how policies are developed and implemented.

The bureau was tipped off to the FBI’s alleged marijuana bug in May 2022, when Eric Sterling, a longtime drug reformer and former congressional staffer, said he discovered the presence of a Maryland police department. reporting cannabis possession citations issued under the state’s decriminalization law at the time as arrests As part of a data sharing partnership with the FBI.

Because other state and local law enforcement agencies don’t seem to report cannabis citations as arrests, Sterling reasoned, the inconsistent practice can significantly skew the FBI’s annual reports, making it harder to draw reasonable policy conclusions from the data.

In 2023—14 months after Sterling sent the query—the office finally responded. However, instead of addressing the apparent issue, the Department of Justice’s (DOJ) Office of the Inspector General’s Investigations Division said it had determined that “the issues you raised are more appropriate for consideration by another DOJ office.” He referred the inquiry to the FBI’s investigative division.

The FBI’s report on cannabis enforcement is also at risk because local and state police are not required to share data to inform the agency’s annual report, which is It provides a comprehensive view of law enforcement activities. The agency itself says that some data may not be comparable to previous years, due to varying levels of participation over time.

—
It’s Marijuana Moment tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25 a month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Meanwhile, the Drug Enforcement Administration (DEA) said in a recent filing The process of reorganizing marijuana is at a standstill in the phase it has been in for monthsdespite the agency head’s prior commitment to senators that he would prioritize the issue if confirmed for the role.

President Donald Trump said in August that he planned to make a decision on his proposal to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA) within weeks.

The overhaul would not legalize marijuana, however, so it remains to be seen how the reform might affect arrest rates reported in future FBI annual reports.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Related Topics:
Continue Reading

Cannabis News

Vivent Biosignals & Green Laniel join forces to bring plant-driven agriculture to the US

Published

16 hours ago

on

January 17, 2026

By











Vivent Biosignals and Green Laniel Consulting have announced a partnership to accelerate plant-driven irrigation and irrigation in key U.S. agricultural markets. Green Laniel Consulting is a US-focused provider of agronomic solutions led by Mauricio Manotas.

By combining Vivent’s ability to decode plant biosignals in real-time using plant biosensors, machine learning and AI with Green Laniel’s deep experience in agronomy, grower operations and US market access, the partnership allows growers to make decisions based on what really matters: how the plant itself is responding.

© Vivent Biosignals

The partnership will cover a variety of crops and production systems, initially plant-driven irrigation and greenhouses for perennial crops, including potatoes, directly guided by plant feedback.

“By combining Vivint’s plant-level intelligence with Green Laniel’s strong presence and agronomic leadership in the US, we are enabling a new generation of plant-driven farming systems. This partnership helps growers improve yields and quality while significantly increasing resource efficiency and sustainability.” says Mauricio Manotas, Green Laniel Consulting.

For more information:
Vivent Biosignals
Tel.: +41 79 5114627
Email: (email protected)
https://vivent-biosignals.com/



Publication date:













Continue Reading

Cannabis News

Indiana Lawmakers Approve Bill To Restrict And Regulate Hemp THC Products

Published

16 hours ago

on

January 17, 2026

By

“In India, we would like some certainty about these products so that those who manufacture and sell them know what our laws are.”

By Leslie Bonilla Muñiz, Indiana Capital Chronicle

Indiana lawmakers want state legislation to join the recently enacted federal ban on intoxicating and synthetic hemp products to counter the growing delta-8 industry.

Lengthy and complex legislation would also regulate less potent products that pass statutory muster.

But, “there will be no demand” for products below the proposed threshold, said Justin Swanson, representing the Midwest Hemp Council and 3Chi, a THC products retailer.

THC is the active ingredient in marijuana.

Sen. Aaron Freeman, R-Indianapolis, admitted to the committee that he would prefer to “wipe all these things off the planet, period,” but that his proposal is “whatever is possible.”

His Senate Bill 250 would mimic Congress’s shutdown of what Freeman described as the “Farm Bill loophole,” referring to 2018 legislation that defined legal hemp as any part of the plant that contains less than 0.3 percent delta-9 THC by dry weight. That definition allowed products containing delta-8, THCA and other intoxicating cannabinoids to proliferate, including in Indiana.

A federal funding law passed in November specifies that all types of THC count. It also limits THC products to just 0.4 milligrams per container, and completely bans those made in labs.

“I think (that’s) what the federal government wanted when they passed the Farm Bill in 2018; I think that’s what everybody had in mind when they copied that language here in Indiana,” said Chris Daniels, chief traffic safety resource attorney for the Indiana Prosecuting Attorneys Council. “The target was very low potency THC.”

An industry group supported the changes.

“It is imperative that Indiana act to align with federal policy in the 2026 legislative session,” said Cory Harris, representative of the American Cannabis and Hemp Trade Association. “Failure to do so means that Indiana’s policy will be stricter than federal law, making Indiana a legal cannabis market.”

The federal provisions will go into effect in November. Freeman’s bill repeats those provisions, but puts them into effect four months earlier, in July.

“It’s sweet that Indiana codified a federal law that will decimate an entire industry in the state,” Swanson said. “The landscape is still unsettled.”

U.S. Rep. Jim Baird — a Republican representing Indiana — introduced a proposal to push the effective date of the federal ban to 2028. President Donald Trump also signed an executive order to expedite the reclassification of marijuana as a less dangerous and less restricted drug.

Swanson said his clients support a “responsible regulatory framework,” and told lawmakers that “the status quo is not acceptable to anyone.”

Freeman’s invoice spends dozens of pages specifically regulating low-THC “hemp-derived cannabinoid products” that would be legalized, primarily with a long-standing 21-and-over requirement.

It also puts the Indiana Alcohol and Tobacco Commission in charge of regulating the rest of the industry, establishing four types of licenses for manufacturers, distributors, retailers and carriers. They would be prohibited from advertising within 1,000 feet of schools, playgrounds and others, with retailers prohibited from operating within the same radius.

Retailers would not be able to deliver products or allow customers to consume them on the spot. Selling the products online would also be illegal, another sticking point for advocates.

Dave Colt, CEO and co-founder of Sun King Brewery, said his homegrown company spent months and more than $100,000 on equipment, research and development for its THC seltzer. Amid declining alcohol sales nationwide, seltzers have allowed Sun King to retain its employees and even grow.

“We also make products for at least a dozen Hoosier small businesses. Without that additional revenue, we would be forced to lay off people and reduce our business significantly,” Colt stated. “We believe the industry wants clear regulations to meet consumer demand.”

Other provisions relate to packaging, labeling and testing.

A fiscal impact study by the nonpartisan Service Agency estimated a financial impact of half a billion dollars annually for ATC to administer and enforce the proposal. The agency will have to hire at least one excise officer in each of the six districts plus Marion County to investigate complaints related to the new regulatory framework.

There will be additional costs for law enforcement training, procurement and online databases, the analysis noted.

The costs could be offset by the permit and other fees collected. The measure would allocate 70 percent of the proceeds to ATC administrative efforts, 20 percent to enforcement, 5 percent to the state’s 988 suicide and crisis hotline and 5 percent to the general fund.

If all tobacco sales certificate holders applied for a retail permit, for example, their application fees would generate $2.1 million. If all are approved, the state would earn an additional $4.6 million, according to LSA’s analysis.

The state seed commissioner would handle licensing for hemp growers and handlers.

Freeman also included a sentence that prevents the Indiana code from immediately reflecting the federal reclassification of marijuana, if that goes forward.

“This bill simply says that we’re not going to automatically follow what the federal government does, that we, the 150 of us, would make that decision, not the federal government for us,” Freeman told his colleagues.

The Senate Commerce and Technology committee also approved an amendment to eliminate an excise tax, as all revenue-raising provisions must be initiated in the House.

The revised legislation passed on a 7-2 party line vote, but the next bill must pass through the Senate Appropriations Committee before going to the House floor.

Previous efforts to ban and regulate intoxicating hemp products have failed.

Asked about his chances this year, Senate Republican Leader Rodric Bray told reporters, “I don’t have that crystal ball,” but added, “I think the bill is in pretty good shape right now.”

“I think in Indiana, we would like some certainty about these products, so that those who manufacture and sell them know what our laws are,” he continued, “and, most importantly, to build in some really meaningful protections for our young people across the state.”

This story was first published by the Indiana Capital Chronicle.

Brendan Cleak’s photo.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Creating a thoughtful cannabis environment for Colorado Springs

Published

2 days ago

on

January 16, 2026

By

In Colorado Springs, where the landscape of legal cannabis is centered around medical use, BioMeds Weed Dispensary Colorado Springs has become a destination for patients seeking high-quality cannabis products and a fair and respectful retail experience. Located at 2301 Rand Avenue, BioMeds has developed a reputation for prioritizing product integrity, patient education and consistent service in response to the brightest trends found in recreationally oriented markets.

Unlike recreational dispensaries, where the volume and variety can sometimes overwhelm, BioMeds takes a deliberate approach. The dispensary offers a good selection of medical cannabis products, including a variety of delivery formats to suit your health needs. These typically include flower strains, tinctures, capsules, topicals, and ingestibles, allowing patients to explore therapeutic cannabis without relying on inhaled methods.

BioMeds understands that patients arrive with different experiences, preferences and conditions. To meet these needs, the dispensary emphasizes informed, non-judgmental customer service based on product knowledge. The staff is trained to explain how different formats work, as well as interpret cannabinoid ratios, identify common terpenes, and select products that match specific wellness goals.

© BioMeds Weed Dispensary Colorado Springs

BioMeds’ product selection is part of the reason patients turn to cannabis. For many, whole flower remains a must-have choice, especially strains that emphasize CBD content, balanced proportions or effect-specific terpene profiles. BioMeds often sells indica, sativa, and hybrids with specific labeling, allowing patients to make informed decisions about onset time, duration, and expected outcome. Beyond flower, tinctures and capsules offer discreet, dose-controlled ways to incorporate cannabis into your daily wellness routine, especially for those managing pain, inflammation, or neurological conditions.

Topicals are also a key part of BioMeds’ offering. These include cannabinoid-infused creams, salves, and lotions intended for topical use. Patients dealing with joint discomfort, muscle tension, or skin conditions often turn to topical products for their non-toxic effects and targeted relief. These products also serve as an entry point for patients exploring cannabis for the first time, especially when faced with systemic or psychoactive effects.

Another category that sees sustained interest in BioMeds is ingestion. These may include low-dose edibles, oils, or beverages tailored to patients seeking long-lasting, absorbed beverages. While recreational edibles in Colorado may gravitate toward high-THC formats, medically focused dispensaries like BioMeds ensure that low-dose, balanced-ratio, CBD-rich formats are available and clearly labeled. Many patients prefer longer-lasting edible formats, especially for managing symptoms at night or for relief throughout the day.

Compliance is a pillar of BioMeds’ operating philosophy. As a medical-only dispensary, the group complies with all Colorado Department of Public Health and Environment (CDPHE) guidelines. Patients must present a valid marijuana card, and all transactions are recorded and monitored according to state protocols. BioMeds does not allow recreational sales and maintains internal training programs to keep employees up-to-date on evolving regulations, labeling requirements and patient protection.

While the dispensary may not offer flashy promotions or themed events often seen in the recreational market, it has placed a special emphasis on medical integrity and personalized service in the Colorado Springs cannabis landscape. For patients who prioritize results over hype, BioMeds offers a consistent experience with proven products and a team that truly understands the nuances of using medical cannabis.

Behind the scenes, BioMeds maintains strong supplier relationships to ensure product availability and freshness. Inventory is regularly reviewed and rotated, and the team communicates directly with manufacturers to maintain transparency around sourcing, testing and packaging. The dispensary favors small and medium-sized Colorado growers who focus on consistency and compliance, with many products undergoing third-party lab testing for cannabinoid content, residual solvents and microbial contamination.

For more information:
BioMeds Weed Dispensary Colorado Springs
biomedsofcolorado.com/

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media